A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma

@inproceedings{Peeters2013ARD,
  title={A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma},
  author={Mirte Peeters and Andrew H. Strickland and Michael R Lichinitser and Attili Satya Suresh and Georgy Moiseevich Manikhas and Jamie Shapiro and Wolf Rogowski and Xiongchuan Huang and Benjamin Wu and Douglas J. Warner and Rajul K. Jain and Niall C. Tebbutt},
  booktitle={British Journal of Cancer},
  year={2013}
}
Background:This phase 2 study evaluated trebananib (AMG 386), an investigational peptide-Fc fusion protein that neutralises the interaction between angiopoietins-1/2 and the Tie2 receptor, plus FOLFIRI as second-line treatment for patients with metastatic colorectal cancer.Methods:Patients had adenocarcinoma of the colon or rectum with progression within 6 months of receiving only one prior fluoropyrimidine/oxaliplatin-based chemotherapy regimen for metastatic disease. All patients received… CONTINUE READING
22 Citations
40 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 40 references

Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial

  • E Van Cutsem, J Tabernero, +9 authors C Allegra
  • 2011
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…